287 related articles for article (PubMed ID: 22664015)
1. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
3. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
4. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
[TBL] [Abstract][Full Text] [Related]
5. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
[TBL] [Abstract][Full Text] [Related]
6. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
8. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
[TBL] [Abstract][Full Text] [Related]
10. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation.
Ghisetti V; Barbui A; Franchello A; Varetto S; Pittaluga F; Bobbio M; Salizzoni M; Marchiaro G
J Med Virol; 2004 Jun; 73(2):223-9. PubMed ID: 15122796
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
15. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
16. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
17. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
18. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
20. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
